On June 9, Deutsche Bank downgraded its investment rating on Intuitive Surgical (ISRG) to 'sell', citing concerns over weakening dominance in the surgical robotics market. Following reports that some hospitals are replacing Da Vinci surgical system tools with cheaper third-party alternatives, ISRG's stock price dropped by approximately 6%.
Today, we analyze ISRG's current situation and assess its investment potential.
About Robotic Surgery Market
https://lojoolodo24.blogspot.com/2025/06/robot-surgery-future-medical-technology.html
1️⃣ Intuitive Surgical (ISRG) Overview
- Company Name: Intuitive Surgical, Inc.
- Ticker: ISRG
- Stock Price: $526.15 (as of June 9, 2025)
- Market Cap: Approx. $188.8B (~256.7 trillion KRW)
Intuitive Surgical develops, manufactures, and sells surgical robotic systems and accessories. With its patent-protected ecosystem, ISRG holds over 80% of the global robotic surgery market share.
Its key products include:
✅ Da Vinci Surgical System – A robotic-assisted surgical platform with a surgeon console, patient-side cart, and high-definition vision system, enabling precise procedures across multiple disciplines (general surgery, urology, gynecology, etc.).
✅ Ion Endoluminal System – A robotic-assisted catheter platform for minimally invasive lung biopsies, allowing accurate tissue sampling for disease diagnosis.
2️⃣ Business Model & Revenue Structure
ISRG follows a "razor and blade" business model, meaning the company sells Da Vinci systems (razor) and generates recurring revenue from surgical instruments and accessories (blades).
Although the Da Vinci system costs between $0.7M and $3.1M, ISRG ensures long-term revenue stability through maintenance contracts and instrument sales.
| Category | Revenue Model | Key Features |
|---|---|---|
| Up-front Revenue | Sales or sales-type leases of Da Vinci & Ion systems | - Da Vinci: $0.7M–$3.1M - Ion: $500K–$815K |
| Recurring Revenue | Instruments, accessories, service contracts, and operating leases | - Instruments: $1,000–$3,600 per surgery - Annual service contracts: Da Vinci: $100K–$225K Ion: $55K–$80K |
🔹 Recurring revenue accounts for approximately 80% of ISRG’s total revenue, consisting of instrument/accessory sales (60%) and service revenue (20%).
🔹 If hospitals continue switching to third-party surgical tools, ISRG’s revenue model and market dominance could be significantly impacted.
📊 ISRG Recurring Revenue Trends
| Year | Recurring Revenue (% of Total Revenue) |
Instrument & Accessory Revenue |
Service Revenue |
|---|---|---|---|
| 2024 | $7.04B (84%) | $5.08B | $1.31B |
| 2023 | $5.94B (83%) | $4.28B | $1.17B |
| 2022 | $4.92B (79%) | $3.52B | $1.02B |
📈 ISRG Da Vinci System Installations
| Year | Total Installed Da Vinci Systems | Growth Rate |
|---|---|---|
| 2024 | 9,902 systems | +15% |
| 2023 | 8,606 systems | +14% |
| 2022 | 7,544 systems | +12% |
3️⃣ ISRG: Strong Company, But Mid-Term Weakness Expected
As mentioned earlier, ISRG's stock dropped 6% following concerns that hospitals are replacing its surgical tools with lower-cost third-party alternatives.
This could negatively impact ISRG’s recurring revenue model and long-term profitability.
✅ Competitive Pressure – Medtronic, CMR Surgical, and Johnson & Johnson are expanding their presence in the surgical robotics space.
✅ Market Share Risk – While ISRG holds a dominant position, competitors could weaken its ecosystem with aggressive pricing strategies and service discounts.
📉 Short-Term Stock Outlook
ISRG’s Q2 earnings report is scheduled for July 17. Until then, its stock price may face further volatility and consolidation.
댓글
댓글 쓰기